CIK 0001664710 · Non-accelerated filer<br>Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 811173868
- Phone
- 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 8-K Event Material agreement
- 4 Insider Changes in Ownership
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13D Stake Beneficial Ownership Report
- 8-A12B Other Registration of Securities
- 8-K Event Material agreement · Shareholder rights changed · Bylaws or fiscal year change · Other events
- 4 Insider Changes in Ownership
- 8-K Event Other events
- 8-K Event Bylaws or fiscal year change
- 8-K Event Regulation FD disclosure
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
Page 8 of 27 · 537 filings